Advanced Chronic DiseasePHSDDNCT07858760
Study of the Care Pathway of Patients Admitted to the Palliative Care Unit of Strasbourg University Hospital From Their Home in 2025
An observational study of Advanced Chronic Disease, run by University Hospital, Strasbourg, France at 1 site in France.
Trial summary
Palliative care aims to improve the quality of life of patients with life-threatening illnesses and their families through early identification, assessment, and management of physical, psychosocial, and spiritual needs. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Advanced Chronic Disease
- How many people
- 80 participants
- Where
- 1 siteFrance
- Study dates
- 22 Feb 2026to 31 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: - Adults patients admitted to the palliative care unit (UnASP) from home or via the emergency department between January 1, 2025, and December 31, 2025
Who may be able to join
- Adults aged ≥18 years
- Patients admitted to the palliative care unit (UnASP) from home or via the emergency department between January 1, 2025, and December 31, 2025
Who cannot join
- Patients transferred from hospital departments other than the emergency department
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Service de soins Palliatifs - CHU de Strasbourg - France
Strasbourg, 67091
Catherine CHEVALIER LAMOUILLE, MD, 33 3 88 11 65 86, catherine.lamouille@chru-strasbourg.fr
Catherine CHEVALIER LAMOUILLE, MD
About this study
Palliative care aims to improve the quality of life of patients with life-threatening illnesses and their families through early identification, assessment, and management of physical, psychosocial, and spiritual needs. The demand for palliative care is steadily increasing due to population aging, the rising prevalence of chronic diseases, and earlier identification of palliative needs. In France, access to palliative care remains insufficient, with only about half of estimated needs currently met.
Early integration of palliative care has been shown to improve quality of life, reduce depressive symptoms, and limit aggressive interventions at the end of life, particularly in oncology, with emerging evidence supporting similar benefits in non-cancer chronic diseases. At the same time, healthcare systems face significant pressure, including limited hospital bed capacity and overcrowded emergency departments, highlighting the importance of optimizing care pathways.
This retrospective study aims to analyze the care pathways of patients admitted to the palliative care unit of Strasbourg University Hospitals from their home in 2025. It will compare direct admissions to those preceded by an emergency department visit and identify clinical, organizational, and social factors associated with direct admission. The findings are expected to inform strategies to improve access to palliative care, promote home-based management when appropriate, and reduce avoidable emergency department utilization.
- Conditions
- Advanced Chronic Disease
- Keywords
- Palliative Care, Advanced Chronic Disease, Care pathways, Emergency department
- Medical subject headings
- Emergencies
What is being measured
The primary outcome is the main question the study is designed to answer.
Admission pathway to the palliative care unit
Classification of patients according to mode of admission: direct admission versus admission following an emergency care pathway (including pre-hospital emergency services, emergency department, or short-stay emergency units), and identification of associated patient and care pathway characteristics.
Measured: At admission (retrospective data collection in 2025)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Oct 2026
- Study start22 Feb 2026
- Primary completion30 Nov 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Advanced Chronic DiseaseStudies of the same condition, open and under way.
- More trials run by University Hospital, Strasbourg, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Strasbourg, France
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07858760
- Sponsor's protocol ID
- RC25_0073
- Acronym
- PHSDD
- Status last verified
- Sep 2026
- First submitted
- 29 Sep 2026
- Last updated
- 5 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of the Care Pathway of Patients Admitted to the Palliative Care Unit of Strasbourg University Hospital From Their Home in 2025
- ClinicalTrials.gov ID
- NCT07858760
- Acronym / sponsor ID
- PHSDD / RC25_0073
- Conditions
- Advanced Chronic Disease
- Keywords
- Palliative Care, Advanced Chronic Disease, Care pathways, Emergency department
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- University Hospital, Strasbourg, FranceUniversity, hospital or other
- Study start
- 22 Feb 2026 (actual)
- Primary completion
- 30 Nov 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 5 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Palliative care aims to improve the quality of life of patients with life-threatening illnesses and their families through early identification, assessment, and management of physical, psychosocial, and spiritual needs. The demand for palliative care is steadily increasing due to population aging, the rising prevalence of chronic diseases, and earlier identification of palliative needs. In France, access to palliative care remains insufficient, with only about half of estimated needs currently met.
Early integration of palliative care has been shown to improve quality of life, reduce depressive symptoms, and limit aggressive interventions at the end of life, particularly in oncology, with emerging evidence supporting similar benefits in non-cancer chronic diseases. At the same time, healthcare systems face significant pressure, including limited hospital bed capacity and overcrowded emergency departments, highlighting the importance of optimizing care pathways.
This retrospective study aims to analyze the care pathways of patients admitted to the palliative care unit of Strasbourg University Hospitals from their home in 2025. It will compare direct admissions to those preceded by an emergency department visit and identify clinical, organizational, and social factors associated with direct admission. The findings are expected to inform strategies to improve access to palliative care, promote home-based management when appropriate, and reduce avoidable emergency department utilization.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- - Adults patients admitted to the palliative care unit (UnASP) from home or via the emergency department between January 1, 2025, and December 31, 2025
Key inclusion criteria (2 listed)
- Adults aged ≥18 years
- Patients admitted to the palliative care unit (UnASP) from home or via the emergency department between January 1, 2025, and December 31, 2025
Key exclusion criteria (1 listed)
- Patients transferred from hospital departments other than the emergency department
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Admission pathway to the palliative care unit
Time frame: At admission (retrospective data collection in 2025)
Classification of patients according to mode of admission: direct admission versus admission following an emergency care pathway (including pre-hospital emergency services, emergency department, or short-stay emergency units), and identification of associated patient and care pathway characteristics.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Advanced Chronic Disease
Not yet recruiting
RELIEVE-HFrEF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure With Reduced EF
Heart Failure and Reduced Ejection Fraction, Heart Failure Chronic
RecruitingPhase 2
A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver Disease (ALD)
Liver Diseases, Alcoholic
Active, not recruiting
LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease
Liver Disease Chronic, End Stage Liver DIsease
Not yet recruitingEarly Phase 1
Sarcopenia in Chronic Kidney Disease (CKD) Patients
Chronic Kidney Disease, Sarcopenia
Not yet recruitingPhase 1/2
Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML
Myeloid Leukemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Advanced Chronic Disease, run by University Hospital, Strasbourg, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Catherine CHEVALIER LAMOUILLE, MD (33 3 3 88 11 65 86, catherine.lamouille@chru-strasbourg.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Admission pathway to the palliative care unit (time frame: At admission (retrospective data collection in 2025)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Oct 2026.